Navigation Links
Hard To Treat Diseases (HTDS) Slavica BioChem Update on Research Activities
Date:4/22/2009

BELGRADE, April 22 /PRNewswire-FirstCall/ - Hard To Treat Diseases (HTDS) www.htdsmedical.com - HTDS chief scientist Dr. Sanja Pekovic provided updates from a recent medical convention held in Antwerpen; Joint Meeting 2009 Anatomische Gesellschaft - Nederlandse Anatomen Vereniging, Antwerpen, 27-30 March 2009.

Dr. Pekovic reported on the results of recent positive testing being conducted related to the CNS disorder multiple sclerosis and in suppression of reactive astrogliosis after brain injury. This led to a number of preliminary talks for future collaboration with other scientists working in the field. A more detailed review of the research results will be posted separately on the Pink Sheets as a supplementary filing shortly. Notably, this work was supported by the European Cooperation in the Field of Scientific and Technical Research (COST) organization.

Dr. Pekovic also reported the scientific team has started some in vitro studies of purine nucleoside analogues (ribavirin, tiazofurin, the drugs we are investigating) effects on microglial cell culture (there is no current data in the literature about their effect on microglia) in collaboration with professor Thomas Herdegen from Kiel University, Germany, who is also a member of COST as a representative of Germany. Over the last 3 months in the lab, our technicians have learned how to establish microglial cell culture, a valuable next step in the continued research.

HTDS will be providing additional funding to further this work, at the IBISS INSTITUT ZA BIOLOSKA ISTRAZIVANJA SINISA STANKOVIC for Project 143005 headed by professor Mirjana Stojiljkovic.

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard To Treat Diseases Inc that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. Hard To Treat Diseases Inc cautions you that any forward-looking information provided by or on behalf of Hard To Treat Diseases Inc is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard To Treat Diseases Inc's actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard To Treat Diseases Inc's control. In addition to those discussed in Hard To Treat Diseases Inc's press releases, public filings, and statements by Hard To Treat Diseases Inc's management, including, but not limited to, Hard To Treat Diseases Inc's estimate of the sufficiency of its existing capital resources, Hard To Treat Diseases Inc's ability to raise additional capital to fund future operations, Hard To Treat Diseases Inc's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard To Treat Diseases Inc's capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard To Treat Diseases Inc does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact corporate@htdsmedical.com, www.htdsmedical.com


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New treatment shows promise against recurrent gynecologic cancers
2. Leading Critical Care Doctor Shifts From Treatment to Empowerment by Helping Americans Create Optimal Health in Their Lives
3. First Patients in United States Receive Innovative Device to Treat Moderate Heart Failure
4. Surveyed Specialists Foresee Greater Use of Parenteral Outpatient Therapy for the Treatment of Osteomyelitis
5. Canadian Medical Device Set to Speed Treatment and Cut Health Care Costs for Common Cause of Vertigo
6. Mayo Clinic researchers formulate treatment combination lethal to pancreatic cancer cells
7. Yashoda Cancer Institute Treats First Patient in India Using RapidArc Radiotherapy Technology
8. For Reducing Mortality, Current and Emerging Therapies Have No Advantage Over Carvedilol in the Treatment of Coronary Heart Disease (Stable Angina)
9. Targeted Treatments Show Mettle Against Advanced Cancers
10. North Carolina Give Kids A Smile! Project Treats Close to 20,000 Children
11. Treatment Algorithm Helps Successfully Manage Diabetes after Transplant Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: